Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models

Cancer Prevention Research

Volumn 8, Issue 3, 2015, Pages 231-239

  Thompson, MatthewD ^a   Grubbs, Clinton J ^b   Bode, AnnM ^c   Reid, Joel M ^d   McGovern, Renee ^d   Bernard, Philip S ^e   Stijleman, Inge J ^e   Green, Jeffrey E ^a   Bennett, Christina ^a   Juliana, M Margaret ^b   Moeinpour, Fariba ^b   Steele, Vernon E ^a   Lubet, Ronald A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MAYO CLINIC CANCER CENTER   (United States)

^e UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; KI 67 ANTIGEN; METFORMIN; METHYLNITROSOUREA; PROTEIN P53; S6 KINASE; TAMOXIFEN; ALKYLATING AGENT; ANTIDIABETIC AGENT; MESSENGER RNA; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PREVENTION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TREATMENT FAILURE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE EXPRESSION; HUMAN VERSUS ANIMAL COMPARISON; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RAT MODEL; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; GENETICS; HUMAN; MAMMARY NEOPLASMS, EXPERIMENTAL; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; TUMOR CELL CULTURE;

ALKYLATING AGENTS; ANIMALS; BIOMARKERS, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MAMMARY NEOPLASMS, EXPERIMENTAL; METFORMIN; METHYLNITROSOUREA; MICE; MICE, INBRED C57BL; MICE, SCID; MICE, TRANSGENIC; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 84927582557     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0181-T     Document Type: Article

References (42)

1. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2012;2:778-90.
2. Dowling R J, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011;9:33.
3. Evans J M, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5.
4. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PloS ONE 2012;7:e33411.
5. Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T, et al. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 2012;30:2844-52.
6. Bosco JL, Antonsen S, Sorensen HT, Pedersen L, Lash TL. Metformin and incident breast cancer among diabetic women: a population-based case- control study in Denmark. Cancer Epidemiol Biomarkers Prev 2011;20:101-11.
7. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigmfor clinical testing of anticancer agents. Breast Cancer Res Treat 2011;126:215-20.
8. Niraula S, Dowling RJ, Ennis M, Chang MC, Done SJ, Hood N, et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 2012;135:821-30.
9. Falcone AB, Mao RL, Shrago E. A study of the action of hypoglycemia-producing biguanide and sulfonylurea compounds on oxidative phosphorylation. J Biol Chem 1962;237:904-9.
10. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310:1642-46.
11. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012;13:251-62.
12. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93.
13. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signaling by decreasing production of cyclic AMP. Nature 2013;494:256-60.
14. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120:2355-69.
15. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia; an update. Nat Rev Cancer 2012;12:159-69.
16. Gallagher EJ, LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci 2011;1243:54-68.
17. Zhu Z, Jiang W, Thompson MD, McGinley JN, Thompson HJ. Metformin as an energy restrictionmimetic agent for breast cancer prevention. J Carcinog 2011;10:17.
18. Bojkova B, Orendas P, Garajova M, Kassayova M, Kutna V, Ahlersova E, et al. Metformin in chemically-induced mammary carcinogenesis in rats. Neoplasma 2009;56:269-74.
19. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea induced rat mammary carcinoma model. Cancer Res 1987;47:4020-4.
20. Lubet RA, Steele VE, DeCoster R, Bowden C, You M, Juliana MM, et al. Chemopreventive effects of the aromatase inhibitor vorozole (R83842) in the methylnitrosourea-induced mammary cancer model. Carcinogenesis 1998;19:1345-51.
21. Chan MM, Lu X, Merchant F, Iglehart JD, Miron PL. Gene expression profiling of NMU-induced ratmammary tumors: cross species comparison with human breast cancer. Carcinogenesis 2005;26:1343-53.
22. Zelazny E, Li B, Anagnostopoulos AM, Coleman A, Perkins AS. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus. Exp Mol Pathol 2001;70:183-93.
23. Lubet RA, Boring D, Steele VE, Ruppert JM, Juliana MM, Grubbs CJ. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis. Cancer Prev Res 2009;2:161-7.
24. Pfefferle AD, Herschkowitz JI, Usary J, Harrell JC, Spike BT, Adams JR, et al. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol 2013;14:R125.
25. Christov K, Grubbs CJ, Shilkaitis A, Juliana MM, Lubet RA. Short term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model. Clin Cancer Res 2007;13:5488-96.
26. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetesmellitus. Br J Clin Pharmacol 1981;12:235-46
27. Alguire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M. Diet and tumor LKB1 expression interact to determine sensitivity to antineoplastic effects of metformin in vivo. Oncogene 2011;30:1174-82.
28. Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, et al. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 2002;62:6376-80.
29. Lu C, Speers C, Zhang Y, Xu X, Hill J, Stenbis E, et al. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor - negative mammary tumors. J Natl Cancer Inst 2003;95:1825-33.
30. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005;40:685-93.
31. Yoshidome K, Shibata MA, Maroulakou IG, Liu ML, Jorcyk CL, Gold LG, et al. Genetic alterations in the development of mammary and prostate cancer in the C3(1)/Tag transgenic mouse model. Int J Oncol 1998;12:449-53.
32. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res 2010;3:1066-76.
33. Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S, et al. Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Transl Oncol 2013;6:649-59.
34. Paik S, Shak S, Tang G, Kim C, Baker J, CroninM, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
35. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor- positive breast cancer. Clin Cancer Res 2010;16:5222-32.
36. Filipits M, Nielsen TO, Rudas M, Greil R, Sẗoger H, Jakesz R, et al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res 2014;20:1298-305.
37. Lynch BJ, GuineeDGJr, Holden JA.HumanDNAtopoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Hum Pathol 1997;28:1180-8.
38. Tokiniwa H, Horiguchi J, Takata D, Kikuchi M, Rokutanda N, Nagaoka R, et al. Topoisomerase II alpha expression andthe Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer. Breast Cancer 2012;19:309-14.
39. Chen S, Huang L, Liu Y, Chen CM, Wu J, Shao ZM. The predictive and prognostic significance of pre-and post-treatment topoisomerase IIa in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer. Eur J Surg Oncol 2013;39:619-26.
40. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67:6745-52.
41. Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 2011;128:783-94.
42. Bonanni B, Putoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri- Gonzaga A, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 2012;30:2593-600.